Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is advancing a mature pipeline of six novel drugs including TEGSEDI™ (inotersen) which is approved in the E.U. Akcea is a global company headquartered in Boston, Massachusetts. Additional information about Akcea Therapeutics is available at www.akceatx.com.